



Clinical Care Guidelines for:

Monitoring the Metabolic Status in Patients Who Are Prescribed Atypical Anti-Psychotic and Anti-Psychotic Medication

OBJECTIVE

To prevent and treat metabolic disorders that may develop as a result of the use of atypical anti-psychotic and anti-psychotic medication.

RATIONALE

Due to the risk of drug related weight gain and the risk of diabetes in patients who are prescribed anti-psychotic and atypical anti-psychotic medications, it is important to monitor metabolic functioning. The American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists and the North American Association for the Study of Obesity have recommended stringent monitoring of metabolic status. Additionally, the American Psychiatric Association in its guidelines for treatment of Bipolar Disorders and Schizophrenia recommends the monitoring of metabolic status in those who are prescribed these types of medications.

RECOMMENDED TREATMENT

1. A patient who is prescribed an anti-psychotic or atypical anti-psychotic should have fasting blood glucose testing and a lipid profile at baseline.
2. After 12 weeks of treatment, a fasting blood glucose test and a lipid profile should be completed.
3. For those in on-going treatment, fasting blood glucose testing and a lipid profile should be completed annually.
4. More frequent monitoring is suggested for children and adolescents.

REFERENCES

American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on anti-psychotic drugs and obesity and diabetes. *Diabetes Care*. 2004; 27; 596-601.

American Psychiatric Association (2004). Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition.

American Psychiatric Association (2002). Practice Guideline for the Treatment of Patients with Bipolar Disorder, Second Edition.

Correll, et al (2009). Cardiometabolic Risk of Second Generation Antipsychotic Medications During First Time Use in Children and Adolescents. *The Journal of the American Medical Association*. 302(16): 1765-1773.

Morrato, et al (2010). Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. *Archives of General Psychiatry*. 67(1): 17-24.